Trastuzumab Rezetecan (SHR-A1811)

DRUG4 trials

Sponsors

The First Affiliated Hospital of Soochow University, Sun Yat-sen University, Ming Chen, Peking University Cancer Hospital & Institute

Conditions

Fallopian Tube CancersHER2-positive Breast CancerNon-Small Cell Lung CancerOvarian CancerPlatinum Sensitive Ovarian Cancer (PSOC)Primary Peritoneal Cancer

Phase 2

Trastuzumab Rezetecan Neoadjuvant Therapy in THP-Insensitive HER2-Positive Early Breast Cancer

RecruitingNCT07647263

The First Affiliated Hospital of Soochow UniversityHER2-positive Breast Cancer

Start: 2026-03-24End: 2031-12-01Target: 124Updated: 2026-06-15

Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Not yet recruitingNCT07776171

Sun Yat-sen UniversityOvarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)

Start: 2026-09-30End: 2030-05-30Target: 176Updated: 2026-08-20

Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy for HER2-Altered Unresectable Stage III Lung Cancer

Not yet recruitingNCT07836543

Ming ChenNon-Small Cell Lung Cancer

Start: 2026-09-01End: 2031-12-01Target: 105Updated: 2026-09-23

Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer

Not yet recruitingNCT07843303

Peking University Cancer Hospital & InstituteFallopian Tube Cancers, Ovarian Cancer, Primary Peritoneal Cancer

Start: 2026-10-22End: 2029-09-30Target: 53Updated: 2026-10-01